Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis
Purpose Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to q...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2019-01, Vol.75 (1), p.99-108 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108 |
|---|---|
| container_issue | 1 |
| container_start_page | 99 |
| container_title | European journal of clinical pharmacology |
| container_volume | 75 |
| creator | Poly, Tahmina Nasrin Islam, Md. Mohaimenul (Rubel) Yang, Hsuan-Chia Li, Yu-Chuan Jack |
| description | Purpose
Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population.
Methods
The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (
n
≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl).
Results
A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860–1.048) with significant heterogeneity (
I
2
= 63.093,
Q
= 43.352,
p
|
| doi_str_mv | 10.1007/s00228-018-2561-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2116124882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2115552792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-fd67d4efeb514e87bb1f02c812f5ab783e19aef6b880be238f99ca93b441d5183</originalsourceid><addsrcrecordid>eNp1kc1u1TAQRi0EoreFB2CDLLFhY5ix8-OwQ1WhSBWwgHXkJOPiNrEvnmSRHa_B6_Ek5HILSEisRpo5881IR4gnCC8QoH7JAFpbBWiVLitU6z2xw8JohVDgfbEDMKiqpoYTccp8A4BlA-ahODGgLWiwO5Hfp6h4ppzC4Ebp4hxUiH500-TmlFc55OWat_4gc-Bbmbz86PJtiJzij2_fWQ6ByTHJEOX8hSSNA-Vxlfu0X0Y3hxRfSScnmp1y0Y0rB34kHng3Mj2-q2fi85uLT-eX6urD23fnr69Ub2o9Kz9U9VCQp67EgmzddehB9xa1L11XW0PYOPJVZy10pI31TdO7xnRFgUOJ1pyJ58fcfU5fF-K5nQL3NI4uUlq41YgV6sJavaHP_kFv0pK3f39RZVnqujlQeKT6nJgz-Xafw-Ty2iK0ByHtUUi7CWkPQtp123l6l7x0Ew1_Nn4b2AB9BHgbxWvKf0__P_UnEWGYnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2115552792</pqid></control><display><type>article</type><title>Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Poly, Tahmina Nasrin ; Islam, Md. Mohaimenul (Rubel) ; Yang, Hsuan-Chia ; Li, Yu-Chuan Jack</creator><creatorcontrib>Poly, Tahmina Nasrin ; Islam, Md. Mohaimenul (Rubel) ; Yang, Hsuan-Chia ; Li, Yu-Chuan Jack</creatorcontrib><description>Purpose
Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population.
Methods
The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (
n
≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl).
Results
A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860–1.048) with significant heterogeneity (
I
2
= 63.093,
Q
= 43.352,
p
< 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738–1.109), 0.96 (95%CI 0.882–1.055), and 0.99 (95%CI 0.841–0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated.
Conclusion
Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-018-2561-y</identifier><identifier>PMID: 30280208</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Analgesics ; Anti-inflammatory agents ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Biomedical and Life Sciences ; Biomedicine ; Geriatrics ; Health risks ; Heterogeneity ; Humans ; Inflammation ; Meta-analysis ; Movement disorders ; Neurodegenerative diseases ; Neuroprotection ; Neuroprotective Agents - administration & dosage ; Neuroprotective Agents - pharmacology ; Nonsteroidal anti-inflammatory drugs ; Observational studies ; Older people ; Parkinson Disease - epidemiology ; Parkinson's disease ; Pharmacoepidemiology and Prescription ; Pharmacology/Toxicology ; Risk</subject><ispartof>European journal of clinical pharmacology, 2019-01, Vol.75 (1), p.99-108</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>European Journal of Clinical Pharmacology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-fd67d4efeb514e87bb1f02c812f5ab783e19aef6b880be238f99ca93b441d5183</citedby><cites>FETCH-LOGICAL-c372t-fd67d4efeb514e87bb1f02c812f5ab783e19aef6b880be238f99ca93b441d5183</cites><orcidid>0000-0001-6026-2748</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-018-2561-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-018-2561-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30280208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poly, Tahmina Nasrin</creatorcontrib><creatorcontrib>Islam, Md. Mohaimenul (Rubel)</creatorcontrib><creatorcontrib>Yang, Hsuan-Chia</creatorcontrib><creatorcontrib>Li, Yu-Chuan Jack</creatorcontrib><title>Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose
Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population.
Methods
The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (
n
≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl).
Results
A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860–1.048) with significant heterogeneity (
I
2
= 63.093,
Q
= 43.352,
p
< 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738–1.109), 0.96 (95%CI 0.882–1.055), and 0.99 (95%CI 0.841–0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated.
Conclusion
Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.</description><subject>Aged</subject><subject>Analgesics</subject><subject>Anti-inflammatory agents</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Geriatrics</subject><subject>Health risks</subject><subject>Heterogeneity</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Meta-analysis</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents - administration & dosage</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Observational studies</subject><subject>Older people</subject><subject>Parkinson Disease - epidemiology</subject><subject>Parkinson's disease</subject><subject>Pharmacoepidemiology and Prescription</subject><subject>Pharmacology/Toxicology</subject><subject>Risk</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1u1TAQRi0EoreFB2CDLLFhY5ix8-OwQ1WhSBWwgHXkJOPiNrEvnmSRHa_B6_Ek5HILSEisRpo5881IR4gnCC8QoH7JAFpbBWiVLitU6z2xw8JohVDgfbEDMKiqpoYTccp8A4BlA-ahODGgLWiwO5Hfp6h4ppzC4Ebp4hxUiH500-TmlFc55OWat_4gc-Bbmbz86PJtiJzij2_fWQ6ByTHJEOX8hSSNA-Vxlfu0X0Y3hxRfSScnmp1y0Y0rB34kHng3Mj2-q2fi85uLT-eX6urD23fnr69Ub2o9Kz9U9VCQp67EgmzddehB9xa1L11XW0PYOPJVZy10pI31TdO7xnRFgUOJ1pyJ58fcfU5fF-K5nQL3NI4uUlq41YgV6sJavaHP_kFv0pK3f39RZVnqujlQeKT6nJgz-Xafw-Ty2iK0ByHtUUi7CWkPQtp123l6l7x0Ew1_Nn4b2AB9BHgbxWvKf0__P_UnEWGYnw</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Poly, Tahmina Nasrin</creator><creator>Islam, Md. Mohaimenul (Rubel)</creator><creator>Yang, Hsuan-Chia</creator><creator>Li, Yu-Chuan Jack</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6026-2748</orcidid></search><sort><creationdate>20190101</creationdate><title>Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis</title><author>Poly, Tahmina Nasrin ; Islam, Md. Mohaimenul (Rubel) ; Yang, Hsuan-Chia ; Li, Yu-Chuan Jack</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-fd67d4efeb514e87bb1f02c812f5ab783e19aef6b880be238f99ca93b441d5183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Analgesics</topic><topic>Anti-inflammatory agents</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Geriatrics</topic><topic>Health risks</topic><topic>Heterogeneity</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Meta-analysis</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents - administration & dosage</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Observational studies</topic><topic>Older people</topic><topic>Parkinson Disease - epidemiology</topic><topic>Parkinson's disease</topic><topic>Pharmacoepidemiology and Prescription</topic><topic>Pharmacology/Toxicology</topic><topic>Risk</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poly, Tahmina Nasrin</creatorcontrib><creatorcontrib>Islam, Md. Mohaimenul (Rubel)</creatorcontrib><creatorcontrib>Yang, Hsuan-Chia</creatorcontrib><creatorcontrib>Li, Yu-Chuan Jack</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poly, Tahmina Nasrin</au><au>Islam, Md. Mohaimenul (Rubel)</au><au>Yang, Hsuan-Chia</au><au>Li, Yu-Chuan Jack</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>75</volume><issue>1</issue><spage>99</spage><epage>108</epage><pages>99-108</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose
Several studies have explored the impact of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Parkinson disease (PD). However, the extent to which NSAIDs may increase or decrease the risk of PD remains unresolved. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between NSAID use and PD risk in the elderly population.
Methods
The electronic databases such as PubMed, EMBASE, Scopus, Google Scholar, and Web of Science were used to search the relevant articles published between January 1990 and December 2017. Large (
n
≥ 1000) observational design studies with a follow-up at least 1 year were considered. Two authors independently extracted information from the included studies. Random effect model was used to calculate risk ratios (RRs) with 95% confidence interval (Cl).
Results
A total of 17 studies with 2,498,258 participants and nearly 14,713 PD patients were included in the final analysis. The overall pooled RR of PD was 0.95 (95%CI 0.860–1.048) with significant heterogeneity (
I
2
= 63.093,
Q
= 43.352,
p
< 0.0001). In the subgroup analysis, the overall pooled RR of PD was 0.90 (95%CI 0.738–1.109), 0.96 (95%CI 0.882–1.055), and 0.99 (95%CI 0.841–0.982) from the studies of North America, Europe, and Asia. Additionally, long-term use, study design, individual NSAID use, and risk of PD were also evaluated.
Conclusion
Despite the neuroprotective potential of NSAIDs demonstrated in some experimental studies, our findings suggest that there is no association between NSAIDs and the risk of Parkinson disease at the population level. Until further evidence is established, clinicians need to be vigilant ensuring that the use of NSAIDs remains restricted to their approved anti-inflammatory and analgesic effect.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30280208</pmid><doi>10.1007/s00228-018-2561-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6026-2748</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2019-01, Vol.75 (1), p.99-108 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2116124882 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Analgesics Anti-inflammatory agents Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - pharmacology Biomedical and Life Sciences Biomedicine Geriatrics Health risks Heterogeneity Humans Inflammation Meta-analysis Movement disorders Neurodegenerative diseases Neuroprotection Neuroprotective Agents - administration & dosage Neuroprotective Agents - pharmacology Nonsteroidal anti-inflammatory drugs Observational studies Older people Parkinson Disease - epidemiology Parkinson's disease Pharmacoepidemiology and Prescription Pharmacology/Toxicology Risk |
| title | Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A25%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-steroidal%20anti-inflammatory%20drugs%20and%20risk%20of%20Parkinson%E2%80%99s%20disease%20in%20the%20elderly%20population:%20a%20meta-analysis&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Poly,%20Tahmina%20Nasrin&rft.date=2019-01-01&rft.volume=75&rft.issue=1&rft.spage=99&rft.epage=108&rft.pages=99-108&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-018-2561-y&rft_dat=%3Cproquest_cross%3E2115552792%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2115552792&rft_id=info:pmid/30280208&rfr_iscdi=true |